Scandinavian ChemoTech: Continued growth in recurring revenues - Redeye

Redeye provides an update on Scandinavian ChemoTech following the Q4 2024 report. The cost control from the company continues to be solid. We nudge down our sales estimates somewhat, but this is offset by regulatory and poduction process-related cost optimisations. We also comment on other events in the quarter, including the separation of business areas and the fact that 50% of revenues are stated to come from treatment kits. We maintain our fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/1085911/scandinavian-chemotech-continued-growth-in-recurring-revenues?utm_source=finwire&utm_medium=RSS